Research and Development

Celsus’ core platform technology is Intimatan™, a sodium salt of repeating L-iduronic acid → 4,6-O-disulfated N-acetyl-D-galactosamine disaccharide units. Intimatan™, blocks both thrombin generation and thrombin activity at the site of vessel injury, the clot, on biomaterial surfaces of blood-interacting medical devices, and in the systemic circulation. It catalyzes heparin cofactor II-dependent inhibition of both soluble and surface-bound thrombin, even in antithrombin-deficient plasma. This action blocks thrombin generation via a sustained action on vessel wall Xa/Va activity, suppressing the thrombin feedback loop, at doses that pose minimal systemic anti-coagulation or bleeding.

Celsus has dedicated facilities and staff for product R&D. New products, and analytical methods, are developed all the way through product pilot scale manufacture, optimization of process controls and process validation. Once completed, the project is moved into production for validation of commercial scale operations. In concert, analytical methods for the commercial product are formalized and transferred to QC for product testing and release.



The R&D labs are equipped with automated potentiometric titration, analytical high performance liquid chromatography (HPLC) systems for molecular weight and charge fractionation analyses as well as disaccharide compositional analyses, preparative HPLC for the purification of oligosaccharides, preparative ultracentrifugation and several pilot scale reactors for process development. Other analytical capabilities available include 500 MHz proton NMR, carbon-13 NMR, MALDI-TOF, and FTIR.